Literature DB >> 2148806

Involvement of FcR+ T cells and of IgG-BF in the control of myeloma cells.

J L Teillaud1, S Brunati, M Elmalek, A Astier, P Nicaise, J Moncuit, C Mathiot, C Job-Deslandre, W H Fridman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2148806     DOI： 10.1016/0161-5890(90)90024-t

Source DB:  PubMed          Journal:  Mol Immunol        ISSN： 0161-5890            Impact factor:   4.407


× No keyword cloud information.
  4 in total

Review 1.  Murine soluble Fc gamma receptors/IgG-binding factors (IgG-BF): analysis of the relation to Fc gamma RII and production of milligram quantities of biologically active recombinant IgG-BF.

Authors:  C Sautès; N Mazières; A Galinha; E Tartour; C Bonnerot; S Amigorena; C Teillaud; R Spagnoli; W H Fridman
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

2.  Increased levels of soluble low-affinity Fc gamma receptors (IgG-binding factors) in the sera of tumour-bearing mice.

Authors:  A Lynch; E Tartour; J L Teillaud; B Asselain; W H Fridman; C Sautès
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

3.  Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma.

Authors:  C Mathiot; J L Teillaud; M Elmalek; V Mosseri; L Euller-Ziegler; A Daragon; B Grosbois; J L Michaux; T Facon; J F Bernard
Journal:  J Clin Immunol       Date:  1993-01       Impact factor: 8.317

4.  Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16.

Authors:  R G Hoover; C Lary; R Page; P Travis; R Owens; J Flick; J Kornbluth; B Barlogie
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.